{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:36:43Z","timestamp":1785317803153,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Theranica"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12325-023-02697-6","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T09:02:15Z","timestamp":1697706135000},"page":"170-181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["One-Year Consistent Safety, Utilization, and Efficacy Assessment of Remote Electrical Neuromodulation (REN) for Migraine Treatment"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4986-4856","authenticated-orcid":false,"given":"Andrea","family":"Synowiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-6447","authenticated-orcid":false,"given":"Alit","family":"Stark-Inbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-6526","authenticated-orcid":false,"given":"Maya","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-4978","authenticated-orcid":false,"given":"Alon","family":"Ironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-5184","authenticated-orcid":false,"given":"Alexander","family":"Mauskop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"2697_CR2","doi-asserted-by":"crossref","unstructured":"Munjal S, Singh P, Reed ML, et al. Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) Study. Headache. 2020;60:416\u201329.","DOI":"10.1111\/head.13708"},{"key":"2697_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60\u20138.","journal-title":"Headache"},{"key":"2697_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002790","volume":"8","author":"H-Z Law","year":"2020","unstructured":"Law H-Z, Chung MH, Nissan G, Janis JE, Amirlak B. Hospital burden of migraine in United States adults: a 15-year national inpatient sample analysis. Plast Reconstr Surg Glob Open. 2020;8:e2790.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2697_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631\u201349.","journal-title":"Neurol Clin"},{"key":"2697_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","volume":"9","author":"PJ Goadsby","year":"2010","unstructured":"Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285\u201398.","journal-title":"Lancet Neurol"},{"key":"2697_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","volume":"3","author":"HC Diener","year":"2004","unstructured":"Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004;3:475\u201383.","journal-title":"Lancet Neurol"},{"key":"2697_CR8","doi-asserted-by":"crossref","unstructured":"Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13:301\u20137.","DOI":"10.1007\/s11916-009-0048-3"},{"key":"2697_CR9","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688\u201395.","journal-title":"Neurology"},{"key":"2697_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343\u20139.","journal-title":"Neurology"},{"key":"2697_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.753736","volume":"2","author":"J Ailani","year":"2022","unstructured":"Ailani J, Rabany L, Tamir S, Ironi A, Starling A. Real-world analysis of remote electrical neuromodulation (REN) for the acute treatment of migraine. Front Pain Res. 2022;2: 753736.","journal-title":"Front Pain Res"},{"key":"2697_CR12","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","volume":"37","author":"E Leroux","year":"2020","unstructured":"Leroux E, Buchanan A, Lombard L, et al. Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020;37:4765\u201396.","journal-title":"Adv Ther"},{"key":"2697_CR13","doi-asserted-by":"crossref","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2022;62(1):111\u201312.","DOI":"10.1111\/head.14245"},{"key":"2697_CR14","doi-asserted-by":"crossref","unstructured":"Alam A, Munjal S, Reed M, et al. Triptan use and discontinuation in a representative sample of persons with migraine: results from Migraine in America Symptoms and Treatment (MAST) Study (P4.10-019). Neurology. 2019;92:P4.10-019.","DOI":"10.1212\/WNL.92.15_supplement.P4.10-019"},{"key":"2697_CR15","doi-asserted-by":"crossref","unstructured":"Tepper DE. Migraine in children. Headache. 2017;57:1021\u20132.","DOI":"10.1111\/head.13091"},{"key":"2697_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1517\/17425255.2015.1043265","volume":"11","author":"A Ferrari","year":"2015","unstructured":"Ferrari A, Baraldi C, Sternieri E. Medication overuse and chronic migraine: a critical review according to clinical pharmacology. Expert Opin Drug Metab Toxicol. 2015;11:1127\u201344.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2697_CR17","doi-asserted-by":"crossref","unstructured":"Tepper SJ. Medication-overuse headache. Continuum (Minneap Minn). 2012;18:807\u201322.","DOI":"10.1212\/01.CON.0000418644.32032.7b"},{"key":"2697_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018;19:50.","journal-title":"J Headache Pain"},{"key":"2697_CR19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1212\/WNL.96.15_supplement.2408","volume":"96","author":"A Mohajer","year":"2021","unstructured":"Mohajer A, Harris L, Keller K, et al. Migraine patients exhibit risk of medication overuse headache with sustained triptan treatment\u2014results from a large-scale real-world claims analysis (2408). Neurology. 2021;96:2408.","journal-title":"Neurology"},{"key":"2697_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s13311-018-0623-6","volume":"15","author":"F Puledda","year":"2018","unstructured":"Puledda F, Shields K. Non-pharmacological approaches for migraine. Neurotherapeutics. 2018;15:336\u201345.","journal-title":"Neurotherapeutics"},{"key":"2697_CR21","doi-asserted-by":"crossref","unstructured":"Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Headache. 2019;59:1158\u201373.","DOI":"10.1111\/head.13628"},{"key":"2697_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pediatrneurol.2023.02.008","volume":"142","author":"A Esparham","year":"2023","unstructured":"Esparham A, Stark-Inbar A, Jekel L, et al. Acute treatment of migraine in adolescents: real-world analysis of remote electrical neuromodulation (REN). Pediatr Neurol. 2023;142:51\u20135.","journal-title":"Pediatr Neurol"},{"key":"2697_CR23","doi-asserted-by":"crossref","unstructured":"Peretz A, Stark-Inbar A, Harris D, et al. Safety of remote electrical neuromodulation for acute migraine treatment in pregnant women: a retrospective controlled survey-study. Headache. 2023;63(7):968\u201370.","DOI":"10.1111\/head.14586"},{"key":"2697_CR24","doi-asserted-by":"crossref","unstructured":"Messali AJ, Yang M, Gillard P, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54:1120\u201330.","DOI":"10.1111\/head.12404"},{"key":"2697_CR25","doi-asserted-by":"crossref","unstructured":"Kati\u0107 BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: what does it mean, why does it matter? Headache. 2010;50:117\u201329.","DOI":"10.1111\/j.1526-4610.2009.01535.x"},{"key":"2697_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/17434440.2023.2202815","volume":"20","author":"M Babaei","year":"2023","unstructured":"Babaei M, Rapoport AM. Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older. Expert Rev Med Devices. 2023;20:433\u201347.","journal-title":"Expert Rev Med Devices"},{"key":"2697_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejpain.2010.02.004","volume":"14","author":"D Yarnitsky","year":"2010","unstructured":"Yarnitsky D, Arendt-Nielsen L, Bouhassira D, et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur J Pain. 2010;14:339\u2013339.","journal-title":"Eur J Pain"},{"key":"2697_CR28","doi-asserted-by":"crossref","unstructured":"Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache. 2019;59:1240\u201352.","DOI":"10.1111\/head.13551"},{"key":"2697_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000966","volume":"6","author":"B Grosberg","year":"2021","unstructured":"Grosberg B, Rabany L, Lin T, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep. 2021;6:e966.","journal-title":"Pain Rep"},{"key":"2697_CR30","doi-asserted-by":"crossref","unstructured":"Nierenburg H, Vieira JR, Lev N, et al. Remote electrical neuromodulation for the acute treatment of migraine in patients with chronic migraine: an open-label pilot study. Pain Ther. 2020;9(2):531\u201343.","DOI":"10.1007\/s40122-020-00185-1"},{"key":"2697_CR31","doi-asserted-by":"crossref","unstructured":"Hershey AD, Lin T, Gruper Y, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache. 2021;61(2):310\u201317.","DOI":"10.1111\/head.14042"},{"key":"2697_CR32","doi-asserted-by":"publisher","unstructured":"Tepper SJ, Rabany L, Cowan RP, et al. Remote electrical neuromodulation for migraine prevention: a double-blind, randomized, placebo-controlled clinical trial. Headache. https:\/\/doi.org\/10.1111\/head.14469.","DOI":"10.1111\/head.14469"},{"key":"2697_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/13696998.2023.2205751","volume":"26","author":"R Cowan","year":"2023","unstructured":"Cowan R, Stark-Inbar A, Rabany L, et al. Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention. J Med Econ. 2023;26:656\u201364.","journal-title":"J Med Econ"},{"key":"2697_CR34","doi-asserted-by":"publisher","unstructured":"Ailani J, Rabany L, Tamir S, Ironi A, Starling A. Real-world analysis of remote electrical neuromodulation (REN) for the acute treatment of migraine. Front Pain Res. 2022. https:\/\/doi.org\/10.3389\/fpain.2021.753736.","DOI":"10.3389\/fpain.2021.753736"},{"key":"2697_CR35","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1093\/pm\/pnaa299","volume":"21","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Lin T, Montal T, Ironi A, Dougherty C. Real-world experience with remote electrical neuromodulation in the acute treatment of migraine. Pain Med. 2020;21:3522\u20139.","journal-title":"Pain Med"},{"key":"2697_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1526-4610.1993.hed3307351.x","volume":"33","author":"GD Solomon","year":"1993","unstructured":"Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the medical outcomes study instrument. Headache. 1993;33:351\u20138.","journal-title":"Headache"},{"key":"2697_CR37","doi-asserted-by":"crossref","unstructured":"Lipton RB, Hutchinson S, Ailani J, et al. Discontinuation of acute prescription medication for migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59:1762\u201372.","DOI":"10.1111\/head.13642"},{"key":"2697_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1468-2982.2004.00694.x","volume":"24","author":"D Dodick","year":"2004","unstructured":"Dodick D, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia. 2004;24:417\u201324.","journal-title":"Cephalalgia"},{"key":"2697_CR39","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1586\/ern.09.47","volume":"9","author":"CA Whyte","year":"2009","unstructured":"Whyte CA, Tepper SJ. Adverse effects of medications commonly used in the treatment of migraine. Expert Rev Neurother. 2009;9:1379\u201391.","journal-title":"Expert Rev Neurother"},{"key":"2697_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2015-000133","volume":"3","author":"J Kim","year":"2015","unstructured":"Kim J, Lee J, Shin CM, Lee DH, Park B-J. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diab Res Care. 2015;3:e000133.","journal-title":"BMJ Open Diab Res Care"},{"key":"2697_CR41","doi-asserted-by":"crossref","unstructured":"Tepper SJ. Opioids should not be used in migraine. Headache. 2012;52:30\u20134.","DOI":"10.1111\/j.1526-4610.2012.02140.x"},{"key":"2697_CR42","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39:1343\u201357.","journal-title":"Cephalalgia"},{"key":"2697_CR43","unstructured":"Ailani J, Kudrow D, Smith TR, et al. Effects of rimegepant 75 mg on monthly migraine days: a 52-week, open-label extension study [abstract no. P-162]. Headache. 2022;62:139\u2013140."},{"key":"2697_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2217\/pmt-2021-0002","volume":"11","author":"PA DeJulio","year":"2021","unstructured":"DeJulio PA, Perese JK, Schuster NM, Oswald JC. Lasmiditan for the acute treatment of migraine. Pain Manag. 2021;11:437\u201349.","journal-title":"Pain Manag"},{"key":"2697_CR45","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894\u2013904.","journal-title":"Brain"},{"key":"2697_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-021-01343-2","volume":"22","author":"C Tassorelli","year":"2021","unstructured":"Tassorelli C, Bragg S, Krege JH, et al. Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain. 2021;22:132.","journal-title":"J Headache Pain"},{"key":"2697_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Reuter U, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023;63:79\u201388.","journal-title":"Headache"},{"key":"2697_CR48","unstructured":"Lipton RB, Kudrow D, Smith TR, et al. Safety and tolerability of rimegepant every other day for preventive treatment of migraine plus as-needed for acute treatment of migraine: results from a 52-week, open-label extension study [abstract no. IOR-09]. Headache. 2022;62(Suppl 1):99."},{"key":"2697_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/head.14427","volume":"63","author":"S Evers","year":"2023","unstructured":"Evers S, Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023;63:165\u20137.","journal-title":"Headache"},{"key":"2697_CR50","doi-asserted-by":"publisher","first-page":"333102422114353","DOI":"10.1177\/03331024221143538","volume":"43","author":"M Ruiz","year":"2023","unstructured":"Ruiz M, Cocores A, Tosti A, Goadsby PJ, Monteith TS. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases series, evaluation of FAERS, and literature review. Cephalalgia. 2023;43:3331024221143538.","journal-title":"Cephalalgia"},{"key":"2697_CR51","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/phar.2725","volume":"42","author":"RH Woods","year":"2022","unstructured":"Woods RH. Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: a pharmacovigilance study. Pharmacotherapy. 2022;42:758\u201367.","journal-title":"Pharmacotherapy"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02697-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T22:05:51Z","timestamp":1705615551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02697-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02697-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alit Stark-Inbar and Alon Ironi are employees of and hold stock options in Theranica Bio-Electronics Ltd.; Maya Weinstein and Andrea Synowiec have consulted for Theranica Bio-Electronics Ltd.; Alexander Mauskop has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study followed the Helsinki Declaration of 1964 and its later amendments. Data was collected from real-world users of the HIPPA-secured Nerivio app<sup>\u00ae<\/sup>. At app signup, patients signed on the terms of using their data, acknowledging that their personal information is provided willingly, and that they agree that their anonymous (deidentified) data may be collected, analyzed, and possibly published for research. Treatments are automatically registered in the Nerivio<sup>\u00ae<\/sup> database (including time of treatment, treatment duration, treatment intensity). At the beginning of each treatment, and again 2\u00a0h after that, users can voluntarily answer a few quick questions about their migraine manifestation and therapies they are using. Thus, an additional ethics approval was not required for the analysis of this type of data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}